Oncolytic Virus Technology for Non-Cancer Applications

This inventive concept leverages the core technology of oncolytic viruses to develop novel treatments for neurological disorders, infectious diseases, and cancer vaccine enhancement, demonstrating the versatility and broad applicability of the original patent.

While oncolytic viruses have shown promising results in cancer treatment, their potential applications extend beyond oncology. The original patent's focus on cancer treatment limits its scope, and this inventive concept addresses the need for innovative solutions in other fields, such as neurological disorders and infectious diseases, where targeted therapies are urgently needed.

The new claims describe a system for treating neurological disorders by administering a recombinant oncolytic virus vector encoding a truncated HSV-TK fragment, which selectively targets and destroys cancer cells while preserving healthy neurons. Additionally, the inventive concept encompasses methods for delivering therapeutic agents, treating infectious diseases, and enhancing cancer vaccine efficacy, all utilizing the truncated HSV-TK fragment. These novel applications build upon the original patent's technology, expanding its reach and potential impact.

The new claims introduce a non-obvious extension of the original patent's technology, applying the oncolytic virus platform to entirely new fields, such as neurological disorders and infectious diseases. The inventive step lies in recognizing the potential of the truncated HSV-TK fragment beyond cancer treatment and developing novel solutions that address specific challenges in these new fields.

Alternative embodiments may include varying the truncated HSV-TK fragment's sequence, using different virus vectors, or combining the oncolytic virus technology with other therapeutic approaches. These variations could lead to further innovations and broaden the scope of the inventive concept.

This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in neurological disorders, infectious diseases, and cancer vaccine development. The market for these novel treatments is substantial, and the inventive concept's versatility and adaptability make it an attractive investment opportunity.